– USA, MA – Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced the appointment of Utpal Koppikar, CFO of Atara Biotherapeutics, to its Board of Directors as the chair of the audit committee.
“I am thrilled to welcome Utpal to Flexion’s Board, as his extensive financial experience leading biotechnology companies makes him an outstanding addition to our Board of Directors,” said CEO, Dr. Michael Clayman. “In addition to Utpal’s anticipated contributions guiding our corporate strategy, I look forward to his stewardship and counsel as chair of our audit committee.”
About Utpal Koppikar
Utpal Koppikar joined Atara Biotherapeutics in June 2018 and oversees Finance, Information Technology, and Investor Relations. Before his tenure with Atara, Mr. Koppikar held several senior financial leadership positions at Gilead Sciences, including VP of Corporate and Operations Finance. During his time there, he led the three-year financial planning process and financial integration of Kite Pharma and played a key role as Gilead’s VP of Finance Europe, Middle East, and Australia partnering with a commercial for multiple HIV and HCV product launches. Before joining Gilead, he served in multiple finance roles of increasing responsibility at Amgen.
Mr. Koppikar commented, “I am honored to join Flexion’s Board of Directors at this exciting point in the company’s evolution. I look forward to supporting Flexion’s management team and my fellow Directors as we work towards realizing the full potential of ZILRETTA® and advancing the company’s two compelling pipeline candidates.”
Mr. Koppikar earned a B.S. in aerospace engineering at the University of Maryland and received an M.S. in aeronautical and astronautical engineering from Stanford University. He also holds an M.B.A. in finance and marketing from The Anderson School at UCLA.
About Flexion Therapeutics
Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company’s core values are focus, ingenuity, tenacity, transparency, and fun.
For more information: https://flexiontherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.